Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.

MLA

Horwitz, Mitchell E., et al. “Omidubicel vs Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase 3 Randomized Study.” Blood, vol. 138, no. 16, Oct. 2021, pp. 1429–40. EBSCOhost, https://doi.org/10.1182/blood.2021011719.

APA

Horwitz, M. E., Stiff, P. J., Cutler, C., Brunstein, C., Hanna, R., Maziarz, R. T., Rezvani, A. R., Karris, N. A., McGuirk, J., Valcarcel, D., Schiller, G. J., Lindemans, C. A., Hwang, W. Y. K., Koh, L. P., Keating, A., Khaled, Y., Hamerschlak, N., Frankfurt, O., Peled, T., … Sanz, G. (2021). Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood, 138(16), 1429–1440. https://doi.org/10.1182/blood.2021011719

Chicago

Horwitz, Mitchell E, Patrick J Stiff, Corey Cutler, Claudio Brunstein, Rabi Hanna, Richard T Maziarz, Andrew R Rezvani, et al. 2021. “Omidubicel vs Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase 3 Randomized Study.” Blood 138 (16): 1429–40. doi:10.1182/blood.2021011719.